These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30157797)

  • 21. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
    Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodríguez A;
    Rev Esp Quimioter; 2014 Sep; 27(3):196-212. PubMed ID: 25229375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Echinocandins: The Expanding Antifungal Armamentarium.
    Aguilar-Zapata D; Petraitiene R; Petraitis V
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
    Liu X; Liu D; Pan Y; Li Y
    J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
    Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
    Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodriguez A;
    Rev Iberoam Micol; 2014; 31(3):157-75. PubMed ID: 25113990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
    Perkhofer S; Hell M; Gustorff B; Von Goedecke A; Illievich U; Kratzer C; Moosbauer W; Wimmer P; Zerlauth U; Nachbaur K; Vogel W; Bellmann R; Schwameis F; Lass-Flörl C
    J Chemother; 2011 Oct; 23(5):285-9. PubMed ID: 22005061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic changes in surgical intensive care unit patients undergoing echinocandin treatment.
    Koch C; Schneck E; Arens C; Markmann M; Sander M; Henrich M; Weigand MA; Lichtenstern C
    Int J Clin Pharm; 2020 Feb; 42(1):72-79. PubMed ID: 31748967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
    Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
    Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial commentary: Prophylactic echinocandin: is there a subgroup of intensive care unit patients who benefit?
    Muldoon EG; Denning DW
    Clin Infect Dis; 2014 May; 58(9):1227-9. PubMed ID: 24550375
    [No Abstract]   [Full Text] [Related]  

  • 35. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anidulafungin in the treatment of patients with invasive candidiasis.
    Kett DH; Cubillos GF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
    Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical review of echinocandins in pediatric patients.
    VandenBussche HL; Van Loo DA
    Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of New Strategies for Echinocandins: Progress in Translational Research.
    Walsh TJ; Azie N; Andes DR
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.
    Holt SL; Drew RH
    Am J Health Syst Pharm; 2011 Jul; 68(13):1207-20. PubMed ID: 21690427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.